Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series B · Jun 2026

City Therapeutics is developing a pipeline of RNA interference (RNAi) therapeutics using a next‑generation RNAi engineering platform. The company has initiated a Phase 1 clinical trial of CITY‑FXI targeting Factor XI and reported positive preclinical data for CITY‑RBP4, a candidate for Stargardt disease. It has announced strategic collaborations with Bausch + Lomb and Biogen and plans to advance two programs to clinical stage this year while progressing additional programs toward the clinic by year‑end 2026. City Therapeutics is based in Cambridge, MA, and has raised over $230 million from life sciences investors to date. The recent $99.5 million Series B is intended to accelerate its platform, expand the pipeline, and support business development and partnership activities.

Participated · Seed · Apr 2026

Tortugas Neuroscience is a clinical-stage, neurology-focused biotech led by CEO Jeff Jonas and based in Framingham, MA. Its pipeline, in-licensed from Eisai Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Ltd., includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies and other CNS indications. Programs center on small-molecule new chemical entities with derisked mechanisms of action designed as once-daily oral formulations with differentiated pharmacological profiles and indication-expansion potential. The company is advancing two lead candidates through Phase 2 clinical trials. The recent $106M Seed and Series A financings are intended to support ongoing research and development and completion of those Phase 2 studies.

Led · Seed · Jul 2025

Pahr Therapeutics is a clinical-stage company focused on developing novel mechanisms to treat pulmonary arterial hypertension (PAH). The company was co-founded by researchers at the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan, including Drs. Yoshikazu Nakaoka, Makoto Okazawa, and Ryotaro Asano. Pahr was incubated at Raven, the incubator of RA Capital Management, and is led by Neil Buckley, a Venture Partner at Raven. Dr. Nakaoka’s research in the molecular pathophysiology of PAH has guided the company’s novel approaches. The company plans to advance into clinical studies early next year and will use the financing proceeds to develop its therapies. Contact information and the company website are provided in the announcement.

Participated · Series B · Apr 2025

Imbria Pharmaceuticals is a clinical-stage company focused on improving cardiac energetics to treat serious cardiovascular diseases. Its lead candidate, ninerafaxstat, is designed to enhance cardiac energy production without affecting heart rate, rhythm, ejection fraction, or blood pressure. The drug is currently being evaluated in FORTITUDE-HCM, a global Phase 2b trial for symptomatic non-obstructive hypertrophic cardiomyopathy, a condition with no approved treatments. The company’s strategy centers on positioning ninerafaxstat as a first-in-class therapy with broad cardiovascular applications. Recent Series B proceeds will fund continued clinical development and trial execution. The financing also expands Imbria’s board, adding representatives from new and existing investors, which may deepen strategic guidance and industry connections. Although the round size remains undisclosed, the expanded investor syndicate signals confidence in the company’s progress and future potential.